| Literature DB >> 33318293 |
Zengli Fang1,2,3,4, Qingcai Meng1,2,3,4, Bo Zhang1,2,3,4, Si Shi1,2,3,4, Jiang Liu1,2,3,4, Chen Liang1,2,3,4, Jie Hua1,2,3,4, Xianjun Yu1,2,3,4, Jin Xu1,2,3,4, Wei Wang1,2,3,4.
Abstract
Increasing evidence has revealed the potential correlation between circulating tumor DNA (ctDNA) and the prognosis of pancreatic cancer, but inconsistent findings have been reported. Therefore, a meta-analysis was performed to evaluate the prognostic value of ctDNA in pancreatic cancer. The Embase, MEDLINE, and Web of Science databases were searched for relevant articles published until April 2020. Articles reporting the correlation between ctDNA and the prognosis of pancreatic cancer were identified through database searches. The pooled hazard ratios (HRs) for prognostic data were calculated and analyzed using Stata software. A total of 2326 patients pooled from 25 eligible studies were included in the meta-analysis to evaluate the prognostic value of ctDNA in pancreatic cancer. Patients with mutations detected or high concentrations of ctDNA had a significantly poorer overall survival (OS) (univariate: HR = 2.54; 95% CI, 2.05-3.14; multivariate: HR = 2.07; 95% CI, 1.69-2.54) and progression-free survival (PFS) (univariate: HR = 2.18; 95% CI, 1.41-3.37; multivariate: HR = 2.20; 95% CI, 1.38-3.52). In conclusion, the present meta-analysis indicates that mutations detected or high concentrations of ctDNA are significant predictors of OS and PFS in patients with pancreatic cancer.Entities:
Keywords: K-ras; circulating tumor DNA; pancreatic cancer; prognosis; systematic review and meta-analysis
Mesh：
Substances：
Year: 2020 PMID： 33318293 PMCID： PMC7880399 DOI： 10.18632/aging.202199
Source DB: PubMed Journal: Aging (Albany NY) ISSN： 1945-4589 Impact factor: 5.682